Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saizen Immunogenicity in Adult Growth Hormone Deficiency
NCT01806298Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2013
- Primary completion
- Mar 2016
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of somatropin in adult growth hormone deficiency (AGHD), sponsored by Merck KGaA. Primary endpoint: Percentage of Subjects Developing Binding Antibodies to Saizen. Started Jun 2013; status: completed.
02
Drugs
somatropin
03
Conditions
adult growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on NCT01806298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806298.